As of November 7, 2026, Minerva Neurosciences, Inc. is a publicly traded company (Nasdaq: NERV); its largest reported holder is Federated Hermes, Inc., with 17.17% on Schedule 13G/A of July 8, 2026, then Balyasny Asset Management L.P. (9.99%). The largest insider holding is Joseph H. Reilly, the chief operating officer, with 20,872 shares (0.04% of shares outstanding), per Form 3 of August 20, 2026 (Schedule 13G/A, July 8, 2026).
Is this your company?
About to sign with, pay or invest in Minerva Neurosciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Minerva Neurosciences, Inc. a real, registered company?
- Minerva Neurosciences, Inc. files with the SEC under CIK 1598646 (its SEC filings).
- Its shares are listed under the ticker NERV on Nasdaq (SEC company record).
- Incorporated in Massachusetts; business address in Burlington, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Minerva Neurosciences, Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Leadership changes: the latest reported is Anthony Aliquo, Chief Accounting Officer (Form 8-K filed 2026-08-12). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Minerva Neurosciences, Inc.'s owners and officers?
Minerva Neurosciences, Inc.: incorporated in Massachusetts; business address in Burlington, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-27).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2023-07-03)
- : Executive Officer (Form D, 2023-07-03)
- : Executive Officer (Form D, 2023-07-03)
- : Director (Form D, 2023-07-03)
- : Director (Form D, 2023-07-03)
- : Director (Form D, 2023-07-03)
- : Director (Form D, 2023-07-03)
- : Director (Form D, 2023-07-03)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-27 | Blackrock, Inc. | 5.1% |
| Schedule 13G/A, 2026-08-14 | Balyasny Asset Management L.P. | 9.99% |
| Schedule 13G/A, 2026-08-13 | Farallon Capital Management, L.L.C. | 9.7% |
| Schedule 13G/A, 2026-07-08 | Federated Hermes, Inc. | 17.17% |
| Schedule 13G, 2026-05-15 | Janus Henderson Group PLC | 9.9% |
| Schedule 13G/A, 2026-05-15 | Balyasny Asset Management L.P. | 9.99% |
| Schedule 13G, 2026-02-20 | Coastlands Capital LP | 9.99% |
| Schedule 13G, 2026-02-17 | Logos Global Management LP | 9.9% |
| Schedule 13G, 2026-02-17 | Balyasny Asset Management L.P. | 9.99% |
| Schedule 13G, 2026-02-12 | Adage Capital Management, L.P. | 6.35% |
| Schedule 13G/A, 2026-02-05 | Dapice Joshua J. | 9.99% |
| Schedule 13G, 2025-12-31 | Vivo Opportunity Fund Holdings, L.P. | 9.99% |
Questions about who owns Minerva Neurosciences, Inc.
Who owns Minerva Neurosciences, Inc.?
On this page, 10 holders' latest ownership filings report 5% or more of Minerva Neurosciences, Inc.: Federated Hermes, Inc. (17.17%, Schedule 13G/A, filed 2026-07-08), Balyasny Asset Management L.P. (9.99%, Schedule 13G/A, filed 2026-08-14), Coastlands Capital LP (9.99%, Schedule 13G, filed 2026-02-20), Dapice Joshua J. (9.99%, Schedule 13G/A, filed 2026-02-05) and Vivo Opportunity Fund Holdings, L.P. (9.99%, Schedule 13G, filed 2025-12-31); 5 more are listed above.
Who are the largest shareholders of Minerva Neurosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Minerva Neurosciences, Inc. on this page are Federated Hermes, Inc. (17.17%), Balyasny Asset Management L.P. (9.99%) and Coastlands Capital LP (9.99%).
When did Federated Hermes, Inc. buy into Minerva Neurosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Federated Hermes, Inc. on this page is the Schedule 13G/A, filed 2026-07-08, reporting 17.17%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Minerva Neurosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Minerva Neurosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Minerva Neurosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-08-12 | Anthony Aliquo | Chief Accounting Officer | appointed | |
| Form 8-K, 2026-08-12 | Fred Ahlholm | Chief Financial Officer | departed | |
| Form 8-K, 2026-04-02 | Geoffrey Race | President | departed | 2026-03-31 |
Which insiders own Minerva Neurosciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief operating officer: 20,872 shares (0.04% of shares outstanding) (Form 3, 2026-08-20).
- , the chief accounting officer: 1,683 shares (0.00% of shares outstanding) (Form 3, 2026-08-20).
Shares outstanding: 49,835,241 as of 2026-11-03, from the company's latest SEC cover page.
How much has Minerva Neurosciences, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-07-03 | $0 | $20M |
Keep reading
More on Minerva Neurosciences, Inc. and the records around it.
Minerva Neurosciences, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Aug 2026
Companies that share a holder
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Arcturus Therapeutics Holdings Inc. (Oct 2026), Forte Biosciences, Inc. (Sep 2026)
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/minerva-neurosciences